Dual versus monotherapy with SGLT2 inhibitor and GLP-1 receptor agonist: PRECIDENTD pragmatic randomized trial.
Deborah J Wexler, Lindsay S Mayberry, Lyndsay A Nelson...
https://pubmed.ncbi.nlm.nih.gov/41456635/Actively Recruiting
Led by Brigham and Women's Hospital · Updated on 2026-04-13
6000
Participants Needed
36
Research Sites
N/A
Total Duration
Researchers are evaluating two treatment options for people with type 2 diabetes who also have established or high-risk atherosclerotic cardiovascular disease ASCVD. This clinical trial aims to compare the total number of heart, kidney, and death events between treatments using sodium-glucose cotransporter-2 inhibitors SGLT2i and glucagon-like peptide-1 receptor agonists GLP-1 RA. The study involves 6,000 participants and seeks to better understand how these medications affect health outcomes in this population. Participants will be randomly assigned to receive either an SGLT2 inhibitor canagliflozin, dapagliflozin, or empagliflozin or a GLP-1 receptor agonist dulaglutide, liraglutide, or semaglutide, all of which have shown cardiovascular benefits. The study is open label, meaning both participants and researchers know which treatment is given. Treatment assignment is balanced evenly between the two groups, and participants will continue their assigned therapy throughout the study. During the trial, researchers will monitor participants for events including heart attacks, strokes, arterial revascularization, hospitalizations for heart failure, kidney failure, kidney transplants, and death. Follow-up will last for an average of about three years. Data will be collected through medical records and electronic health information, with ongoing tracking of health status and treatment adherence to assess the total number of these cardiovascular and kidney-related events.
CONDITIONS
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
B
Brendan Everett, MD, MPH
M
Maureen Malloy
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Brigham and Women's Hospital
Lead Sponsor
Patient-Centered Outcomes Research Institute
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | SGLT2 inhibitor | GLP‑1 receptor agonist | Standard of care (metformin ± RAS inhibitor) |
|---|---|---|---|
| What it is | One randomized arm assigned to a sodium‑glucose cotransporter‑2 inhibitor (empagliflozin, dapagliflozin, or canagliflozin) | One randomized arm assigned to a glucagon‑like peptide‑1 receptor agonist (dulaglutide, liraglutide, or semaglutide) | Standard care often includes metformin with a renin‑angiotensin system inhibitor for cardiorenal protection |
| Role in the trial | Active treatment arm within the randomized trial | Active treatment arm within the randomized trial | Not part of the trial; provided as external context |
| Primary use | Prevention of cardiovascular, kidney disease, and death events in type 2 diabetes | Prevention of cardiovascular, kidney disease, and death events in type 2 diabetes | Routine glucose‑lowering and renal‑cardiovascular risk reduction using metformin and RAS inhibitors |
| How it is given or performed | Participants receive one SGLT2 inhibitor of clinician’s choice | Participants receive one GLP‑1 receptor agonist of clinician’s choice | Metformin plus ACE inhibitor or ARB according to guideline recommendations |
| Evidence status | Evidence from prior outcome trials supports cardiovascular and kidney protection | Prior trials show cardiovascular and kidney benefits for GLP‑1 receptor agonists | Metformin and RAS inhibitors reduce cardiovascular and renal risk in type 2 diabetes |
| Important risks | Known risks include genital infections, volume depletion and rare diabetic ketoacidosis | Known risks include gastrointestinal symptoms and possible pancreatitis | Metformin risks include gastrointestinal upset; RAS inhibitors can affect kidney function and potassium levels |
| Important limitations | Trial evaluates class not specific agents; benefit in prevention setting still being established | Same limitation as SGLT2i arm: class‑based evaluation in prevention context | Standard care may not provide the same level of organ protection as newer drug classes |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 3 years
Participants receive therapy with either an SGLT2 inhibitor or a GLP-1 receptor agonist medication class to prevent cardiovascular and diabetic kidney disease.
Regular visits as needed to fill prescriptions and adjust medications for safety
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Deborah J Wexler, Lindsay S Mayberry, Lyndsay A Nelson...
https://pubmed.ncbi.nlm.nih.gov/41456635/Brigham and Women's Hospital
Lead Sponsor
Patient-Centered Outcomes Research Institute
Collaborating Sponsor